Logo
Your free order overview
You currently have not items to display
Logo
Your contact details

This is a required field

Logo
Thank you!

Thank you for choosing Janssen Medical Cloud for ordering your materials.

Back to Johnson & Johnson Medical Cloud
open
Logo

What is IMBRUVICA®?

IMBRUVICA® is the first Bruton’s tyrosine kinase (BTK) inhibitor, indicated for the treatment of CLL, MCL and WM.1,2

IMBRUVICA® in chronic lymphocytic leukaemia (CLL)
IMBRUVICA® in mantle cell lymphoma (MCL)
IMBRUVICA® in Waldenström's macroglobulinaemia (WM)
Celebrating 250,000 patients treated with IMBRUVICA®[1]
Achieve IGHV excellence

How determining your patient’s IGHV status could help shape their treatment pathway

Explore IMBRUVICA® resources

Explore IMBRUVICA® resources

Component not published? componentType is undefined.

Logo
© Janssen Sciences Ireland UC. This site is published by Janssen Sciences Ireland UC which is solely responsible for its content. It is intended for Irish healthcare professionals. Third party trademarks used herein are trademarks of their respective owners.
Legal NoticePrivacy PolicyCookie PolicyContact us
Cookie Settings